NCT01207921已完成1 期
A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 3
- 主要终点
- To evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after ASCT, as measured by dropout rate.
研究概览
简要总结
The purpose of this study to evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after autologous transplant
详细描述
Primary Objectives
-To evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after autologous stem cell transplant, as measured by dropout rate.
Secondary Objectives
- To assess overall survival, event free survival, and progression free survival.
- To establish the adverse event profile of long-term maintenance therapy with lenalidomide in this patient population.
- To assess the conversion of partial response/stable disease post-ASCT to complete response.
- To evaluate changes in immune cell number and function and plasma proteins before, during, and after lenalidomide therapy (correlative studies).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must have histologically documented classical Hodgkin lymphoma that is recurrent or refractory to standard chemotherapy.
- •Core biopsies are acceptable if they contain adequate tissue for primary diagnosis and immunophenotyping. If the original diagnostic specimen is not available, relapsed or refractory specimens may be used. Bone marrow biopsies as the sole means of diagnosis are not acceptable; however, they may be used in conjunction with nodal biopsies. Fine needle aspirates (FNA) are not acceptable. Pathology reports must be submitted with the appropriate CRFs, and the actual biopsy specimens are not requested for central review. Patients with cHL have one of the following WHO subtypes:
- •Nodular sclerosis Hodgkin lymphoma
- •Lymphocyte-rich Hodgkin lymphoma
- •Mixed cellularity Hodgkin lymphoma
- •Lymphocyte-deplete Hodgkin lymphoma cHL patients without one of these subtypes designated cHL not otherwise specified are also eligible.
- •NOTE: Patients with nodular lymphocyte-predominant HL are not eligible.
- •Patient must have undergone autologous stem cell transplant (ASCT) between 60 and 90 days prior to study registration.
- •Patient must be ≥ 18 years old.
- •Patient must have an ECOG performance status of ≤ 2 at study entry.
- •Patient must have adequate hematologic, renal, and hepatic function as defined by:
- •Absolute neutrophil count ≥ 1000 / μL
- •Platelets ≥ 30,000 / μL
- •Serum creatinine ≤ 1.5 X institution upper limit of normal (ULN)
- •Total bilirubin ≤ 1.5 mg/dL
- •AST (SGOT) and ALT (SGPT) ≤ 3 x ULN (if not attributed to cHL)
- •Patient must be disease free of prior malignancies for ≥ 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
- •Patient must understand and voluntarily sign an informed consent form.
- •Patient must be able to adhere to the study visit schedule and other protocol requirements.
- •If a female of childbearing potential (FCBP), patient must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal [birth control pills, injections, or implants], tubal ligation, partner's vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods if needed
- •A FCBP is defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
- •A FCBP must have two negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to starting study drug. The first pregnancy test must be performed within 10-14 days prior to the start of study drug and the second pregnancy test must be performed within 24 hours prior to prescribing the study drug. The subject may not receive study drug until the Investigator has verified that the results of these pregnancy tests are negative.
- •If male, patient must agree to use a latex condom during sexual contact with FCBP while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
- •Patient must be able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).
- •Patient must be registered into the mandatory Revlimid REMS® program and be willing and able to comply with the requirements of Revlimid REMS®.
排除标准
- •Patient who has undergone allogeneic stem cell transplantation.
- •Patient who shows evidence of progressive disease during salvage chemotherapy or following ASCT.
- •Patient has any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent him/her from signing the informed consent form.
- •Patient has any condition, including the presence of laboratory abnormalities, which places him/her at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- •Patient has used any other anti-cancer drug or therapy, including experimental, within 30 days of initiation of lenalidomide treatment (radiation therapy is allowed within 30 days).
- •Patient has known hypersensitivity to thalidomide.
- •Patient developed erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- •Patient has any prior use of lenalidomide.
- •Patient is known to be positive for HIV or infectious hepatitis, type A, B, or C.
- •Patient is pregnant or breastfeeding.
- •Patient has concurrent use of other anti-cancer agents or treatments.
研究组 & 干预措施
Arm 1
Experimental
Lenalidomide 15 mg/day Cycle 1 (28 days).
If no unacceptable side effects Cycle 2 (28 days) will be lenalidomide 20 mg/day.
If no unacceptable side effects Cycles 3 thru 18 (28 days for each cycle) will be lenalidomide 25 mg/day.
干预措施: Lenalidomide (Drug)
结局指标
主要结局
To evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after ASCT, as measured by dropout rate.
时间窗: 12 months
Will be described by the proportion of patients who drop out of the study for drug-related reasons at or before 12 months
次要结局
- Progression-free survival (PFS)(Until progression (estimated to be 10 years))
- Evaluate immune response(Through 30 days after end of treatment)
- Overall survival (OS)(Until death (estimated to be 10 years))
- Adverse event profile(From start of treatment through 30 days following completion of treatment)
- Conversion of partial response/stable disease post-ASCT to complete response.(1 year)
- Event-free survival (EFS)(Until progression or death (whichever comes first) - estimated to be 10 years)
研究者
研究点 (3)
Loading locations...
相似试验
终止
1 期
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT02018523Jun Zhang7
Unknown
2 期
Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell LymphomaRelapsed and/or Refractory Non-Hodgkin T-cell LymphomaNCT03730740Samsung Medical Center79
已完成
2 期
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple MyelomaMultiple MyelomaNCT00847639Center for International Blood and Marrow Transplant Research30
已完成
1 期
Dose-finding of Lenalidomide as Maintenance in Multiple MyelomaMultiple MyelomaNCT00778752Universitätsklinikum Hamburg-Eppendorf24
已完成
1 期
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2AAdult Acute Promyelocytic Leukemia With PML-RARAAdult Grade III Lymphomatoid GranulomatosisAdult Nasal Type Extranodal NK/T-Cell LymphomaAlkylating Agent-Related Acute Myeloid LeukemiaAngioimmunoblastic T-Cell LymphomaAnaplastic Large Cell LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueHepatosplenic T-Cell LymphomaIntraocular LymphomaLymphomatous Involvement of Non-Cutaneous Extranodal SiteMature T-Cell and NK-Cell Non-Hodgkin LymphomaNodal Marginal Zone LymphomaPrimary Cutaneous B-Cell Non-Hodgkin LymphomaRecurrent Adult Burkitt LymphomaProlymphocytic LeukemiaPost-Transplant Lymphoproliferative DisorderRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Immunoblastic LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-Cell Leukemia/LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides and Sezary SyndromeRecurrent Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hairy Cell LeukemiaRichter SyndromeSmall Intestinal LymphomaSplenic Marginal Zone LymphomaT-Cell Large Granular Lymphocyte LeukemiaTesticular LymphomaWaldenstrom MacroglobulinemiaNCT01254578National Cancer Institute (NCI)17